Download Free Novartis Book in PDF and EPUB Free Download. You can read online Novartis and write the review.

The Swiss pharmaceutical industry is world-famous, and of today's top five global pharmaceutical businesses, two are Swiss - Roche and Novartis. Novartis was created in 1996 from a merger between three other major companies, Ciba, Geigy and Sandoz (the merger was the biggest ever in business history worldwide up to that point), but despite being a relatively new name, it is rooted in over 150 years of history. Focusing on the emergence of Novartis, this authoritative book is also the fascinating story of how Switzerland's pharmaceutical industry grew out of early dye-production for textiles in the mid nineteenth century, scored major triumphs with the introduction of products such as DDT and Valium in the twentieth century, and developed into the far-reaching international healthcare providers of today.
One of the world's leading pharmaceutical companies, the Swiss multinational Novartis traces its history and that of its predecessor companies back to the first dye factories in Basel in the early 19th century.This second edition of the company's history covers early exports and expansion abroad, the unparalleled upsurge of the chemical industry in Basel during the First World War and then the emergence of pharmaceuticals in the interwar years. The enormous challenges of the Second World War were followed by an economic boom in the 1950s and 60s, the merger of CIBA and Geigy, the numerous diversifications in the 1970s and 80s, the merger of Ciba and Sandoz to found Novartis, and finally the first 25 years of Novartis. Those 25 years have included innovations in pharmaceuticals and medicine, and game-changing technologies such as the modification of T-cells.In addition to the running text, fifteen thematic articles outline the company's widely different innovations: from CIBA's early hormone preparations to the outstanding graphic design of Geigy Design, from revolutionary drugs like Sandimmune or Gleevec right through to the Novartis Campus project.
One of the world's leading pharmaceutical companies, the Swiss multinational Novartis traces its history and that of its predecessor companies back to the first dye factories in Basel in the early 19th century. This second edition of the company's history covers early exports and expansion abroad, the unparalleled upsurge of the chemical industry in Basel during the First World War and then the emergence of pharmaceuticals in the interwar years. The enormous challenges of the Second World War were followed by an economic boom in the 1950s and 60s, the merger of CIBA and Geigy, the numerous diversifications in the 1970s and 80s, the merger of Ciba and Sandoz to found Novartis, and finally the first 25 years of Novartis. Those 25 years have included innovations in pharmaceuticals and medicine, and game-changing technologies such as the modification of T-cells. In addition to the running text, fifteen thematic articles outline the company's widely different innovations: from CIBA's early hormone preparations to the outstanding graphic design of Geigy Design, from revolutionary drugs like Sandimmune or Gleevec right through to the Novartis Campus project.
The following analysis illustrates the underlying trends and relationships of U.S. issued patents of the subject company. The analysis employs two frequently used patent classification methods: US Patent Classification (UPC) and International Patent Classification (IPC). Aside from assisting patent examiners in determining the field of search for newly submitted patent applications, the two classification methods play a pivotal role in the characterization and analysis of technologies contained in collections of patent data. The analysis also includes the company’s most prolific inventors, top cited patents as well as foreign filings by technology area.
The business to business trade publication for information and physical Security professionals.
Leading researchers, from the Novartis group that pioneered Gleevec/GlivecTM and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.